Characterizing the Disease-Initiating Cell Population In a Murine Model of Jak2V617F+Myeloproliferative Neoplasm

被引：0
|
作者：
Mullally, Ann
Lane, Steven W. [2 ]
Poveromo, Luke
Al-Shahrour, Fatima
Kutok, Jeffery [1 ]
Ebert, Benjamin L. [3 ]
机构：
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[2] Childrens Hosp, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：144 / 145
页数：2
相关论文
共 50 条
  • [21] Prevalence of JAK2V617F, CALR in Philadelphia Positive and Negative Myeloproliferative Neoplasm
    Abedi, Elham
    Karimi, Mehran
    Cohan, Nader
    Haghpanah, Sezaneh
    Yaghobi, Ramin
    Azarpira, Negar
    Moghadam, Mohamad
    Bayat, Elahe
    Farokhian, Farnoush
    Mohammadi, Hamid
    Lak, Elahe Razmara
    Golafshan, Habib Allah
    Ramzi, Mani
    GALEN MEDICAL JOURNAL, 2021, 10
  • [22] A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression
    Marty, C.
    Lacout, C.
    Droin, N.
    Le Couedic, J-P
    Ribrag, V.
    Solary, E.
    Vainchenker, W.
    Villeval, J-L
    Plo, I.
    LEUKEMIA, 2013, 27 (11) : 2187 - 2195
  • [23] A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression
    C Marty
    C Lacout
    N Droin
    J-P Le Couédic
    V Ribrag
    E Solary
    W Vainchenker
    J-L Villeval
    I Plo
    Leukemia, 2013, 27 : 2187 - 2195
  • [24] Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha.
    Lane, Steven W.
    Mullally, Ann
    ONCOTARGET, 2013, 4 (04) : 500 - 501
  • [25] Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm
    Peyro-Saint-Paul, Helene
    Hermitte, Fabienne
    BLOOD, 2010, 116 (11) : 1994 - 1995
  • [26] Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model
    Bianco, Thiago Mantello
    Coelho-Silva, Juan L.
    Pereira-Martins, Diego A.
    Scheucher, Priscila Santos
    Weinhauser, Isabel
    Alves Silva, Antonio Bruno
    Silva, Cleide Lucia
    Mullally, Ann
    Kobayashi, Susumu S.
    Rego, Eduardo M.
    Traina, Fabiola
    Figueiredo-Pontes, Lorena Lobo
    BLOOD, 2019, 134
  • [27] Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
    Yang, Yue
    Akada, Hajime
    Nath, Dipmoy
    Hutchison, Robert E.
    Mohi, Golam
    BLOOD, 2016, 127 (26) : 3410 - 3423
  • [28] Targeting Endothelial-to-Mesenchymal Transition in a 3D iPSC-Based Model of JAK2V617F+Myeloproliferative Neoplasms
    Caduc, Madeline J.
    Lopez, Cristina Baquero
    Grasshoff, Martin
    Buhl, Eva Miriam
    Mabrouk, Mohamed H. Elsafi
    Ernst, Sabrina
    Wong, Dickson W. L.
    Mueller-Newen, Gerhard
    Vogt, Michael
    Eschweiler, Joerg
    Boor, Peter
    Ackermann, Maximilian
    Franzen, Julia
    Costa, Ivan G.
    Zenke, Martin
    Brummendorf, Tim H.
    Koschmieder, Steffen
    de Toledo, Marcelo Szymanski
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S421 - S422
  • [29] Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm
    Li, Z. C.
    Fu, H. J.
    Wang, Z. M.
    Yang, S.
    Xu, H. Z.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (03):
  • [30] Discussion of the correlation between JAK2V617f mutation and thromboembolism in myeloproliferative neoplasm patients
    Xia, L.
    Wu, J-S
    Ding, K-Y
    Zeng, Q-S
    Cai, X-Y
    Zhu, W-B
    Wu, L-L
    Liu, X.
    Yang, H-Z
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 635 - 636
12345